Skip to content
value.today
Humacyte, Inc. logo

Humacyte, Inc.

HUMA
$125 Mmarket cap on Oct 28, 2026-55.0% since Jan 2024
Compare
World rank
#17,923
Revenue
$2 M
For year ending December-2025
Net income
$-41 M
-2001.5% margin
SEC filing
Employees
—

Humacyte, Inc. in brief

Humacyte, Inc. is a listed company in the Biotechnology industry, based in Durham, North Carolina, USA. Its market value was $125 M on 28 October 2026, which makes it the 17,923rd largest listed company in the world and the 3,402nd largest in the USA on this site. In the year to December 2025 it had sales of $2 M and a net loss of $41 M. Laura E. Niklason is its chief executive. Its largest product and service lines by sales in 2025 were Contract Revenue (32%). Its shares trade under the symbol HUMA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Humacyte, Inc.

Humacyte is a Clinical Stage Biotechnology Platform company developing universally implantable bioengineered human tissue at a commercial scale with the goal of improving the lives of patients and transforming the practice of medicine. The company total assets are 101 million USD as on 2020. The headquarters is in USA.

Humacyte, Inc. timeline

3 events, 2020–2021
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering as Alpha Healthcare Acquisition Corp.
    Final prospectus filed with the SEC on 18 September 2020; shares registered for exchange trading on 17 September 2020. The blank-check company later merged with the business that carries the name today.
  4. 2021
  5. ✎
    Renamed Humacyte, Inc.
    Formerly Alpha Healthcare Acquisition Corp..

Events of Humacyte, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$174 M$348 M$522 M$696 M2023202420252026

World rank over time

▼ down 6,069 places since 2022
2022-01-07: #11893#11,89320222022-12-25: #17129#17,12920222023-07-30: #15668#15,66820232024-01-05: #16214#16,21420242026-03-08: #8759#8,75920262026-08-01: #15913#15,91320262026-10-13: #18536#18,53620262026-10-28: #17962#17,9622026

Rank in USA: #2,984 (Jan 2022) · #3,500 (Dec 2022) · #3,175 (Jul 2023) · #2,998 (Jan 2024) · #1,638 (Mar 2026) · #3,186 (Aug 2026) · #3,456 (Oct 2026) · #3,406 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
51.9×
Price / book
40.2×
Free cash flow yield
-84.7%
Net margin (TTM)
-3932.0%
Operating margin
-5301.0%
Return on equity
-3046.9%
Liabilities / assets
97.3%
Net debt
$-15M
R&D / revenue
3397.1%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2020: revenue —, net income $-67M—FY20Fiscal year ending Dec 2021: revenue —, net income $-26M—FY21Fiscal year ending Dec 2022: revenue —, net income $-12M—FY22Fiscal year ending Dec 2023: revenue —, net income $-111M—FY23Fiscal year ending Dec 2024: revenue —, net income $-149M—FY24Fiscal year ending Dec 2025: revenue $2M, net income $-41M$2MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$2M—$-108M$-41M-2001.5%
Dec 2024——$-114M$-149M—
Dec 2023——$-100M$-111M—
Dec 2022——$-85M$-12M—
Dec 2021——$-81M$-26M—
Dec 2020——$-65M$-67M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-105M$1M$-106M$-0.26—
Dec 2024$-98M$2M$-100M$-1.26—
Dec 2023$-73M$2M$-76M$-1.07—
Dec 2022$-71M$1M$-72M$-0.12—
Dec 2021$-81M$0M$-81M$-0.66—
Dec 2020$-56M$0M$-56M$-11.54—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$2M
Net income, trailing 12 months
$-95M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-21M—Dec ’24Three months to Mar 2025: revenue $1M, net income $39M$1MMar ’25Three months to Jun 2025: revenue $0M, net income $-38M$0MJun ’25Three months to Sep 2025: revenue $1M, net income $-18M$1MSep ’25Three months to Dec 2025 (from the annual report): revenue $0M, net income $-25M$0MDec ’25Three months to Mar 2026: revenue $1M, net income $-18M$1MMar ’26Three months to Jun 2026: revenue $0M, net income $-37M$0MJun ’26Three months to Sep 2026: revenue $1M, net income $-16M$1MSep ’26

Latest quarter to Sep 2026: revenue $1M (+37.3% on a year earlier), net income $-16M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Humacyte, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$2 M
Operating income
$-108 M
Net income
$-41 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$116 M
Total liabilities
$113 M
Total equity
$3 M

As of December-2025

Top 100 institutional investors in Humacyte, Inc.#

As of Sep 30, 2026
129 institutions held 54.4 M shares (about 19.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 14.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Humacyte, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC10,964,108+856,429 (+8.47%)3.95%$6 MNov 13, 2026
2ANTIPODES PARTNERS Ltd8,258,350-1,845,297 (-18.26%)2.97%$4 MNov 5, 2026
3BlackRock, Inc.4,565,633-274,296 (-5.67%)1.64%$2 MNov 13, 2026
4Great Point Partners LLC3,750,0000 (0.00%)1.35%$2 MNov 16, 2026
5UBS Group AG3,007,277+163,784 (+5.76%)1.08%$2 MNov 10, 2026
6Marshall Wace, LLP2,996,553+2,814,722 (+1547.99%)1.08%$2 MNov 13, 2026
7Geode Capital Management, LLC2,676,475+491,250 (+22.48%)0.96%$1 MNov 6, 2026
8Citadel Advisors LLC1,733,130+289,754 (+20.07%)0.62%$1 MNov 16, 2026
9Susquehanna International Group, LLP1,670,302-28,941 (-1.70%)0.60%$1 MNov 16, 2026
10Vanguard Fiduciary Trust Co1,599,496+418,220 (+35.40%)0.58%$1 MNov 13, 2026
11Charles Schwab Investment Management Inc1,376,120+22,605 (+1.67%)0.50%$1 MNov 16, 2026
12Private Advisor Group, LLC947,765-17,326 (-1.80%)0.34%$0 MNov 10, 2026
13LPL Financial LLC938,041-87,494 (-8.53%)0.34%$0 MNov 6, 2026
14Wealth Effects LLC919,720+225,800 (+32.54%)0.33%$0 MOct 23, 2026
15State Street Corp900,646+58,109 (+6.90%)0.32%$0 MNov 12, 2026
16Vanguard Portfolio Management LLC767,569+199,048 (+35.01%)0.28%$0 MNov 13, 2026
17Lion Point Capital, LP650,0000 (0.00%)0.23%$0 MNov 16, 2026
18Northern Trust Corp586,572+130,099 (+28.50%)0.21%$0 MNov 16, 2026
19Woodline Partners LP500,5820 (0.00%)0.18%$0 MNov 16, 2026
20Invesco Ltd.448,633+193,099 (+75.57%)0.16%$0 MNov 12, 2026
21Gsa Capital Partners LLP334,510-671,199 (-66.74%)0.12%$0 MNov 16, 2026
22Morgan Stanley260,475-84,647 (-24.53%)0.09%$0 MNov 13, 2026
23LJI Wealth Management, LLC252,500-17,000 (-6.31%)0.09%$0 MOct 28, 2026
24Goldman Sachs Group Inc242,915-343,609 (-58.58%)0.09%$0 MNov 16, 2026
25United Asset Strategies, Inc.209,6080 (0.00%)0.08%$0 MOct 28, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Humacyte, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Hudson Bay Capital Management LP195,000-180,000 (-48.00%)0.07%$0 MNov 13, 2026
27Catalyst Funds Management Pty Ltd162,119-45,781 (-22.02%)0.06%$0 MNov 12, 2026
28Bridgeway Capital Management, LLC157,378-2,622 (-1.64%)0.06%$0 MNov 16, 2026
29Empowered Funds, LLC157,378New0.06%$0 MNov 13, 2026
30Creative Planning149,129+37,787 (+33.94%)0.05%$0 MNov 2, 2026
31Group One Trading LLC136,595-20,548 (-13.08%)0.05%$0 MNov 10, 2026
32Bolton Securities Corporation120,0000 (0.00%)0.04%$0 MNov 12, 2026
33AQR Capital Management LLC114,051-2,483,083 (-95.61%)0.04%$0 MNov 16, 2026
34LaSalle St. Investment Advisors, LLC111,574-2,295 (-2.02%)0.04%$0 MNov 16, 2026
35Renaissance Technologies LLC110,271New0.04%$0 MNov 12, 2026
36Cetera Investment Advisers109,186+2,475 (+2.32%)0.04%$0 MNov 13, 2026
37Miramontes Capital, LLC108,6950 (0.00%)0.04%$0 MOct 19, 2026
38Endowment Wealth Management, Inc.105,4180 (0.00%)0.04%$0 MNov 3, 2026
39Vanguard Global Advisers, LLC104,782+54,916 (+110.13%)0.04%$0 MNov 13, 2026
40Two Sigma Investments, LP92,783+63,235 (+214.01%)0.03%$0 MNov 16, 2026
41Bank Of America Corp /de/88,507-490,085 (-84.70%)0.03%$0 MNov 16, 2026
42Schonfeld Strategic Advisors LLC86,580-75,059 (-46.44%)0.03%$0 MNov 16, 2026
43Kovack Advisors, Inc.82,6000 (0.00%)0.03%$0 MNov 13, 2026
44Barclays PLC76,001+36,321 (+91.53%)0.03%$0 MNov 6, 2026
45Advisors Capital Management, LLC73,657New0.03%$0 MNov 12, 2026
46Concurrent Investment Advisors, LLC71,479+2,500 (+3.62%)0.03%$0 MOct 16, 2026
47Engineers Gate Manager LP61,907+48,000 (+345.15%)0.02%$0 MNov 16, 2026
48BNP Paribas Financial Markets57,634-152,151 (-72.53%)0.02%$0 MNov 12, 2026
49Integrity Alliance, LLC.57,3000 (0.00%)0.02%$0 MOct 29, 2026
50Beacon Pointe Advisors, LLC56,000+20,000 (+55.56%)0.02%$0 MNov 16, 2026
51Bank of New York Mellon Corp55,8440 (0.00%)0.02%$0 MNov 5, 2026
52Osaic Holdings, Inc.53,672-2,900 (-5.13%)0.02%$0 MNov 12, 2026
53China Universal Asset Management Co., Ltd.50,687+15,353 (+43.45%)0.02%$0 MOct 28, 2026
54Clarus Wealth Advisors46,545+6,574 (+16.45%)0.02%$0 MOct 13, 2026
55Letko, Brosseau & Associates Inc45,9500 (0.00%)0.02%$0 MNov 6, 2026
56Raymond James Financial Inc45,670-4,132 (-8.30%)0.02%$0 MNov 12, 2026
57Merit Financial Group, LLC43,475-9,337 (-17.68%)0.02%$0 MNov 6, 2026
58Chicago Partners Investment Group LLC42,489+9,143 (+27.42%)0.02%$0 MOct 27, 2026
59Financial Advisors Network, Inc.41,6380 (0.00%)0.01%$0 MNov 13, 2026
60Tower Research Capital LLC (TRC)33,234-6,448 (-16.25%)0.01%$0 MNov 16, 2026
61R Squared Ltd30,844-961 (-3.02%)0.01%$0 MNov 6, 2026
62Victory Capital Management Inc29,268+6,006 (+25.82%)0.01%$0 MNov 10, 2026
63Lazari Capital Management, Inc.26,444+12,000 (+83.08%)0.01%$0 MOct 20, 2026
64Trust Co of Kansas24,0000 (0.00%)0.01%$0 MNov 6, 2026
65MAI Capital Management22,418-12,242 (-35.32%)0.01%$0 MNov 12, 2026
66Columbia Advisory Partners LLC21,958+2,000 (+10.02%)0.01%$0 MOct 15, 2026
67Hamilton Lane Advisors LLC21,8930 (0.00%)0.01%$0 MOct 21, 2026
68Jpmorgan Chase & Co21,534+7,944 (+58.45%)0.01%$0 MNov 12, 2026
69Waverly Advisors, LLC20,495-3,177 (-13.42%)0.01%$0 MNov 16, 2026
70Great Valley Advisor Group, Inc.19,7540 (0.00%)0.01%$0 MNov 9, 2026
71Independent Advisor Alliance19,500+5,000 (+34.48%)0.01%$0 MNov 10, 2026
72Jain Global LLC18,945-95,613 (-83.46%)0.01%$0 MNov 16, 2026
73HighTower Advisors, LLC18,293-4,049 (-18.12%)0.01%$0 MNov 10, 2026
74HUB Investment Partners, LLC18,250New0.01%$0 MNov 3, 2026
75PFG Investments, LLC17,842-50 (-0.28%)0.01%$0 MNov 12, 2026
76Mariner, LLC17,565-157,410 (-89.96%)0.01%$0 MNov 12, 2026
77Prosperity Wealth Management, Inc.17,500—0.01%$0 MNov 16, 2026
78Rather & Kittrell, Inc.17,3500 (0.00%)0.01%$0 MNov 12, 2026
79Trilogy Capital Inc.17,0500 (0.00%)0.01%$0 MOct 20, 2026
80Jones Financial Companies Lllp16,8700 (0.00%)0.01%$0 MNov 13, 2026
81Onyx Bridge Wealth Group LLC16,500+5,000 (+43.48%)0.01%$0 MOct 16, 2026
82Regions Financial Corp16,3990 (0.00%)0.01%$0 MNov 5, 2026
83Imprint Wealth LLC16,3630 (0.00%)0.01%$0 MNov 16, 2026
84Wealth Watch Advisors, INC16,363New0.01%$0 MNov 16, 2026
85Wealth Enhancement Advisory Services, LLC15,702-34,328 (-68.61%)0.01%$0 MOct 13, 2026
86Uniting Wealth Partners, LLC15,6090 (0.00%)0.01%$0 MNov 6, 2026
87Accredited Investors Inc.15,6000 (0.00%)0.01%$0 MNov 3, 2026
88Valeo Financial Advisors, LLC15,400-4,500 (-22.61%)0.01%$0 MOct 8, 2026
89CFS Investment Advisory Services, LLC15,0000 (0.00%)0.01%$0 MOct 19, 2026
90Nuveen, LLC14,660+3,290 (+28.94%)0.01%$0 MNov 10, 2026
91Mirae Asset Global Investments Co., Ltd.14,196+4,266 (+42.96%)0.01%$0 MOct 29, 2026
92Brookstone Capital Management13,984+730 (+5.51%)0.01%$0 MOct 22, 2026
93Fifth Third Bancorp13,180+12,486 (+1799.14%)0.00%$0 MNov 5, 2026
94Brown Advisory Inc13,1290 (0.00%)0.00%$0 MNov 16, 2026
95Clearview Wealth Management LLC13,0000 (0.00%)0.00%$0 MOct 16, 2026
96Tudor Investment Corp Et Al12,3000 (0.00%)0.00%$0 MNov 16, 2026
97Vanguard Personalized Indexing Management, LLC11,874New0.00%$0 MNov 16, 2026
98Act Wealth Management, LLC11,3790 (0.00%)0.00%$0 MOct 9, 2026
99Key Client Fiduciary Advisors, LLC10,020-1,700 (-14.51%)0.00%$0 MOct 19, 2026
100Truist Financial Corp10,000New0.00%$0 MOct 30, 2026

All 129 institutional investors, with who bought and sold →

Mutual funds holding Humacyte, Inc.#

39 funds hold shares worth $15 M (about 6.0% of the company). Since their previous reports 22 added shares and 55 sold, selling $3 M net.
Mutual funds holding Humacyte, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.7.72 M$6 M2.8%<0.01%+46%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.2.12 M$2 M0.76%<0.01%+25%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors1.44 M$1 M0.52%0.01%+18%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC839,278$1 M0.30%<0.01%+117%May 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.835,684$1 M0.30%<0.01%+9.1%May 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.728,581$1 M0.26%<0.01%−1.6%May 31, 2026
🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc.474,574$1 M0.17%<0.01%−0.9%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC276,545$0 M0.10%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC233,838$0 M0.08%<0.01%+6.8%May 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.415,181$0 M0.15%<0.01%+277%Jul 31, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC243,339$0 M0.09%<0.01%+88%Jul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC101,891$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors167,033$0 M0.06%<0.01%+2.5%Jun 30, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.96,784$0 M0.03%<0.01%+12%May 31, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC160,000$0 M0.06%0.08%−24%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.136,276$0 M0.05%<0.01%+136%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.131,718$0 M0.05%<0.01%+26%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company70,822$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.68,970$0 M0.02%<0.01%+1.4%May 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC91,962$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC62,744$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.35,933$0 M0.01%<0.01%+3.0%May 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC68,576$0 M0.02%<0.01%+13%Jul 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.55,838$0 M0.02%<0.01%+132%Jun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC30,744$0 M0.01%<0.01%+19%Jul 31, 2026
🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION14,991$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.23,262$0 M<0.01%<0.01%+24%Jul 31, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.9,770$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC7,628$0 M<0.01%<0.01%+14%May 31, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC11,911$0 M<0.01%<0.01%+21%Jun 30, 2026
🇺🇸 Nuveen Nasdaq 100 Dynamic Overwrite FundNuveen Fund Advisors, LLC11,370$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC5,965$0 M<0.01%<0.01%−38%May 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC6,034$0 M<0.01%<0.01%−37%May 31, 2026
🇺🇸 Morgan Stanley Pathway Small-Mid Cap Equity ETFCONSULTING GROUP ADVISORY SERVICES LLC3,350$0 M<0.01%<0.01%−5.2%May 31, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC3,124$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC5,134$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC4,026$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC3,863$0 M<0.01%<0.01%+18%Jun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC1,149$0 M<0.01%<0.01%+28%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 39 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Humacyte, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$90 K
5 purchases, 3 insiders
Sold, 12 months
$41 K
2 sales, 2 insiders
Net, 12 months
$49 K
open market only
Insiders on file
16
since
$718 K-$8.0 M$0May 2024: bought $718 K (4 trades), sold $8.0 M (8 trades)May 24Jun 2024: bought $30 K (4 trades), sold $5.9 M (10 trades)Aug 2024: bought $28 K (3 trades), sold $6.0 M (7 trades)AugSep 2024: bought $0 (0 trades), sold $2.4 M (6 trades)Nov 2024: bought $8 K (2 trades), sold $6.6 M (6 trades)NovDec 2024: bought $20 K (1 trades), sold $0 (0 trades)Apr 2025: bought $146 K (6 trades), sold $0 (0 trades)AprAug 2025: bought $0 (0 trades), sold $3.7 M (6 trades)May 2026: bought $60 K (2 trades), sold $41 K (2 trades)MayAug 2026: bought $25 K (2 trades), sold $0 (0 trades)Sep 2026: bought $6 K (1 trades), sold $0 (0 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Humacyte, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Keith Anthony JonesDirectorBuy+10,000$0.560$6 K50,000Form 4
filed Keith Anthony JonesDirectorBuy+10,000$0.690$7 K40,000Form 4
filed Keith Anthony JonesDirectorBuy+30,000$0.590$18 K30,000Form 4
filed Kathleen SebeliusDirectorBuy+56,818$0.880$50 K148,025Form 4
filed Shamik J. ParikhChief Medical OfficerSell10b5-1 plan-45,887$0.900—272,713Form 4
filed Dale A. SanderCFO and Chief Corp. Dev. OffSell10b5-1 plan-45,887$0.900$41 K267,213Form 4
filed Michael T. ConstantinoDirectorBuy+11,000$0.890$10 K43,950Form 4
filed Shamik J. ParikhChief Medical OfficerGrant or award+311,100——318,600Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Humacyte, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
28.1 M
14.5% of shares · 7.19 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 42,552 shares at $0.45
  • : 183,998 shares at $0.40
  • : 700 shares at $0.35
  • : 99,686 shares at $0.39
  • : 62,702 shares at $0.48

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Humacyte, Inc. scorecard#

Passes 3 of the 15 checks that could be worked out: strongest in financial health (2 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 28, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median40.2×Price to book 40.2× against Biotechnology's median of 2.9×.
    • ✗Price to sales below its peers' median51.9×Price to sales 51.9× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-84.7%Free cash flow is -84.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.26 vs -1.26Diluted EPS -0.26 in fiscal 2025 against -1.26 the year before (report's currency).
    • ✓Net income higher than five years earlier-$41 M-$41 M in fiscal 2025 against -$67 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$41 MNet income -$41 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 5
    • ✓Short-term assets cover short-term liabilities3.7×Current ratio 3.69 at the end of fiscal 2025.
    • ✗Debt below equity11.4×Debt to equity 11.40 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $15 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-10.62Z-score -10.62 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year33.5%Diluted shares up 33.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Humacyte, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Humacyte, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020
Income statement
Revenue2.00————
Cost of revenue9.70————
Research and development698977636154
General and administrative312623232112
Operating expenses—114100868266
Total costs and expenses110114————
Operating income−108−114−100−85−81−65
Interest and finance income2.64.15.52.60.00.3
Interest expense and finance costs119.36.66.24.32.2
Other non-operating income (expense)67−34−117355−1.9
Income before tax−41—————
Income tax000000
Net income attributable to shareholders−41−149−111−12−26−67
Earnings per share, basic-0.26-1.26-1.07-0.12-0.66-11.54
Earnings per share, diluted-0.26-1.26-1.07-0.12-0.66-11.54
Shares, weighted average (basic)158118103103405.8
Shares, weighted average (diluted)158118103103405.8
Balance sheet
Cash and cash equivalents50458015021840r
Short-term investments——02.18.00
Receivables0.40r00.00.20.1
Inventory140————
Other current assets3.32.9r2.82.33.7—
Current assets68488315422941r
Property, plant and equipment192327303541
Right-of-use (leased) assets00.60.60.7r0.70.8
Total assets116138128204287107r
Accounts payable5.44.56.51.62.12.3r
Current liabilities182018201111r
Lease liabilities (non-current)—0.50.60.6r0.70.7
Total liabilities1131911158716436r
Retained earnings−727−686−537−427−415−388r
Shareholders' equity3.1−5314117122−350r
Total equity—————−350
Total liabilities and equity116138128204287107r
Shares outstanding1931301041031035.8
Cash-flow statement
Share-based compensation9.86.16.86.2104.7
Cash from operating activities−105−98−73−71−81−56
Capital expenditure−0.9−1.6−2.3−1.0−0.2−0.3
Cash from investing activities−0.9−1.6−0.24.8−8.2−0.3
Debt issued————03.3
Debt repaid−880————
Shares issued————2420
Cash from financing activities611144.5−1.42672.1
Change in cash−4414−69−68178−54
Report10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Humacyte, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$1 M68%
  • Contract Revenue$1 M32%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Humacyte, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$5.2 M
Dr. Niklason
Other top executives, average
$2.1 M
the CEO earned 2.5× this
$100 invested is now
$34
Humacyte, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Niklason$5.2 M−$725 K$2.1 M$34
2024Laura E. Niklason$905 K$2.9 M$678 K$178

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Humacyte, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Directors and officers 1 · Material agreement 9 · Agreement ended 2 · New debt 2 · Unregistered share sale 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 7

Humacyte, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Material agreement8-K
Bylaws or fiscal year changedShareholder vote8-K
Delisting notice8-K
Material agreement8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Agreement ended8-K
Material agreementNew debtUnregistered share sale8-K
Agreement ended8-K
Results announced8-K
Material agreement8-K
Material agreementNew debt8-K
Results announced8-K
Bylaws or fiscal year changedShareholder vote8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Lobbying by Humacyte, Inc.#

$120 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues, medicare/medicaid and defense.

Lobbying, 2025
$120 K
#1,194 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
3
in 2025
2026 so far
$150 K
  • Health Issues5 reports
  • Medicare/Medicaid2 reports
  • Defense2 reports

Lobbying firms hired in 2025

Capitol Hill Consulting Group $100 K · G2G Consulting $20 K · DLA Piper LLP (US)

Humacyte, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$150 K—3
2025$120 K—6
2024$60 K—6
2023$10 K—2
2021$110 K—3
2020$200 K—4
2019$200 K—4
2018$200 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Humacyte, Inc.” and “Humacyte”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Humacyte, Inc. compares in Biotechnology

  • Market cap$125 M · higher than 39% of 726
  • Revenue$2 M · higher than 30% of 647
  • Price / sales51.9× · lower than 17% of 339
  • Price / book40.2× · lower than 4% of 534
  • FCF yield-84.7% · higher than 12% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Humacyte, Inc.🇺🇸$125 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 28, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Humacyte, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Humacyte, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Humacyte, Inc.? Suggest a correction